Nymox Pharmaceutical (NASDAQ:NYMX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMXGet Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Shares of NYMX opened at $1.22 on Wednesday. The company has a market capitalization of $110.14 million, a P/E ratio of -8.13 and a beta of 1.12. Nymox Pharmaceutical has a one year low of $0.94 and a one year high of $2.87. The business’s 50 day simple moving average is $1.47 and its 200-day simple moving average is $1.51.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Nymox Pharmaceutical by 21.8% in the 3rd quarter. Geode Capital Management LLC now owns 50,731 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 9,086 shares in the last quarter. Advisor Group Holdings Inc. boosted its holdings in shares of Nymox Pharmaceutical by 365.4% in the 3rd quarter. Advisor Group Holdings Inc. now owns 12,100 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 9,500 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Nymox Pharmaceutical by 15.9% in the 2nd quarter. Morgan Stanley now owns 76,239 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 10,471 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Nymox Pharmaceutical by 1,834.9% in the 2nd quarter. Millennium Management LLC now owns 323,364 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 306,652 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Nymox Pharmaceutical by 71.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 48,736 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 20,236 shares in the last quarter. 1.59% of the stock is currently owned by institutional investors and hedge funds.

About Nymox Pharmaceutical (Get Rating)

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.

See Also

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.